ANI Pharmaceuticals Inc (ANIP) Expected to Announce Earnings of $1.09 Per Share

Equities analysts expect ANI Pharmaceuticals Inc (NASDAQ:ANIP) to post $1.09 earnings per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for ANI Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $1.11 and the lowest estimate coming in at $1.07. ANI Pharmaceuticals reported earnings of $0.90 per share during the same quarter last year, which suggests a positive year over year growth rate of 21.1%. The business is expected to report its next quarterly earnings report on Thursday, March 1st.

On average, analysts expect that ANI Pharmaceuticals will report full-year earnings of $3.93 per share for the current year, with EPS estimates ranging from $3.90 to $3.95. For the next fiscal year, analysts forecast that the firm will post earnings of $4.67 per share, with EPS estimates ranging from $4.50 to $4.84. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow ANI Pharmaceuticals.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 EPS for the quarter, topping analysts’ consensus estimates of $0.99 by $0.12. The company had revenue of $48.16 million for the quarter, compared to the consensus estimate of $48.12 million. ANI Pharmaceuticals had a return on equity of 22.40% and a net margin of 4.45%. The firm’s revenue for the quarter was up 25.0% on a year-over-year basis. During the same period in the previous year, the business earned $1.09 earnings per share.

ANIP has been the topic of a number of research analyst reports. Canaccord Genuity set a $77.00 target price on ANI Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, December 29th. ValuEngine upgraded ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 4th. TheStreet upgraded ANI Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Thursday, November 16th. BidaskClub upgraded ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, January 5th. Finally, Zacks Investment Research downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $71.00.

A number of hedge funds and other institutional investors have recently modified their holdings of ANIP. Schwab Charles Investment Management Inc. increased its stake in ANI Pharmaceuticals by 9.1% during the second quarter. Schwab Charles Investment Management Inc. now owns 42,428 shares of the specialty pharmaceutical company’s stock worth $1,986,000 after acquiring an additional 3,522 shares during the last quarter. Legal & General Group Plc increased its stake in ANI Pharmaceuticals by 12.5% during the second quarter. Legal & General Group Plc now owns 14,581 shares of the specialty pharmaceutical company’s stock worth $683,000 after acquiring an additional 1,618 shares during the last quarter. BNP Paribas Arbitrage SA increased its stake in ANI Pharmaceuticals by 44.6% during the second quarter. BNP Paribas Arbitrage SA now owns 2,152 shares of the specialty pharmaceutical company’s stock worth $101,000 after acquiring an additional 664 shares during the last quarter. Wells Fargo & Company MN increased its stake in ANI Pharmaceuticals by 81.8% during the second quarter. Wells Fargo & Company MN now owns 16,058 shares of the specialty pharmaceutical company’s stock worth $752,000 after acquiring an additional 7,226 shares during the last quarter. Finally, Alliancebernstein L.P. increased its stake in ANI Pharmaceuticals by 32.7% during the second quarter. Alliancebernstein L.P. now owns 10,550 shares of the specialty pharmaceutical company’s stock worth $494,000 after acquiring an additional 2,600 shares during the last quarter. 55.05% of the stock is currently owned by institutional investors.

Shares of ANI Pharmaceuticals (NASDAQ ANIP) opened at $69.94 on Friday. The company has a debt-to-equity ratio of 0.83, a current ratio of 3.45 and a quick ratio of 2.39. The company has a market capitalization of $812.68, a PE ratio of 109.28 and a beta of 2.90. ANI Pharmaceuticals has a 52-week low of $42.23 and a 52-week high of $74.70.

WARNING: “ANI Pharmaceuticals Inc (ANIP) Expected to Announce Earnings of $1.09 Per Share” was published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/01/21/ani-pharmaceuticals-inc-anip-expected-to-announce-earnings-of-1-09-per-share.html.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Get a free copy of the Zacks research report on ANI Pharmaceuticals (ANIP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply